Deutsche Bank analyst Justin Bowers started Amedisys with a Buy rating and $155 price target as part of his broader research note into the Post-Acute sector in the Healthcare Facilities industry, saying the fundamentals of the public home health pure-plays are attractive despite payment reform beginning in 2020. The analyst is positive on the turnaround efforts by Amedisys management from the 2014 trough, which include nearly 500bps of margin expansion, the return of same-store growth, and doubling the mix of hospice EBITDA contribution. Bowers adds that the operational focus of the company's management on the turnaround and the preparation for Patient-Driven Groupings Model, or PDGM, increase his conviction in its ability to navigate the payment reform.